The pharmacokinetic principle behind the clinical decision to administer vancomycin as an extended infusion (over 4 hours) rather than the traditional 1-hour infusion for resistant gram-positive infections is based on:

• A Vancomycin exhibits time-dependent bactericidal killing (not concentration-dependent), and AUC/MIC is the pharmacodynamic index predicting efficacy; extended infusion maintains free drug concentrations above MIC for a longer time fraction, optimising AUC/MIC target attainment when MICs are elevated ✓
• B Rapid infusion of vancomycin causes 'red man syndrome' via direct mast cell degranulation; extended infusion reduces this histamine release reaction
• C Vancomycin demonstrates post-antibiotic effect (PAE) that is prolonged by extended infusion, requiring drug to be present only transiently at the beginning of each dosing interval
• D Extended infusion reduces vancomycin's volume of distribution, maintaining higher plasma concentrations and improving renal penetration for UTI treatment

Explanation

Vancomycin's bactericidal activity is time-dependent (unlike aminoglycosides which are concentration-dependent). For vancomycin, the key PD index is AUC/MIC (target AUC 400-600 mg·h/L per current ASHP/IDSA guidelines). When organism MIC is elevated (e.g., hVISA with MIC 2-4 mg/L), achieving the AUC/MIC target with standard 1-hour infusions requires doses that cause nephrotoxicity. Extending infusion to 4-6 hours maintains serum concentrations above the MIC (improving T>MIC) for the entire dosing interval without increasing total dose, improving AUC/MIC attainment and reducing toxicity. While option B (red man syndrome prevention) is also true, it is not the pharmacodynamic rationale for extended infusion against resistant organisms.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.